Audio Conference

Conducting Drug Trials in Asia Pacific Dr. Helen Ormandy Director, Centres of Excellence Covance Asia Pacific Purchase recording US$199

Purchase recording of this audio conference 

With constant pressure to reduce the cost of drug development and to find eligible subjects for clinical trials, developing areas of the world are of increasing interest to trial sponsors. But how does the quality of data compare with traditional sites? And what about the rate of recruitment? Do these alternative sites really offer a substantial benefit in terms of time and cost savings? This presentation, the second in a series featuring speakers from Covance addressing alternative site selection, will focus on the opportunities and the reality of performing clinical trials in the Asia Pacific market.

This audio conference will address:

• Benefits and challenges of performing clinical trials in the Asia Pacific region
• The general healthcare, regulatory and clinical trial environment in Asia Pacific
• A comparison of the developing markets in India and China vs. the relatively established environments in Singapore and Australia
• Outlook for the future
  

About the speaker:

Based in Sydney, Australia, Dr. Helen Ormandy is the Director of the Centres of Excellence for Covance Asia Pacific. She is responsible for managing clinical trials on behalf of pharmaceutical and biotech companies across a broad range of therapeutic areas and phases in the Asia Pacific region, including Australia, New Zealand, Malaysia, Singapore, Korea, Vietnam, Hong Kong, Taiwan, Thailand, India and China.

After completing a PhD in Neurobiology, Helen joined the pharmaceutical industry as a postdoctoral scientist within the Endocrinology Division of Roussel Uclaf, Paris. She later moved to the clinical research section and spent several years doing international clinical trials, mainly in hormone replacement therapies and antibiotics. Helen later spent seven years with Astra (now AstraZeneca), where she became the clinical research manager for its Australian affiliate. There, she managed phase I-IV trials in Australia and New Zealand, including multinational registration trials and local trials in the therapeutic areas of respiratory, gastrointestinal, cardiovascular, central nervous system, oncology, analgesia and anaesthesia.

Who should attend?

• Senior Management
• Risk Managers
• Clinical Directors and VPs
• Global Project Directors
• Senior Clinical Managers
• Senior Operational Managers
• Outsourcing Directors and VPs
• Outsourcing Managers
• Feasibility Managers
  

This audio conference is classified as General Interest.

Registration Options

• Purchase recording US$199